Reckitt Benckiser Group plc (RBGPF)
NEUTRALFondamental
52
Prix
$5150.00
Capitalisation boursière
$32.48B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.
Comment l'entreprise gagne de l'argent
Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.
Avantage concurrentiel
Marque · ÉtroitReckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.
Ce qui stimule la demande
DéfensifMost of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.
Les arguments en faveur
Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.
Les arguments contre
Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.
Written by the editors, published on 18 août 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$13.35B
12 derniers mois jusqu'au dernier trimestre publié — estimation à partir de ratios par action
Résultat net
$2.81B
12 derniers mois jusqu'au dernier trimestre publié — estimation à partir de ratios par action
Flux de trésorerie libre
$3.09B
Capitaux propres totaux
$5.67B
Passif total
$10.25B
Ratio de liquidité général
0.59
Couverture des intérêts
-
Dette/EBITDA
2.86
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$2156.36
Prix actuel
$5150.00
Marge de sécurité
-138.8%
Fourchette de juste valeur
$1401.63 - $2911.08
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
1169.99
ROE
48.0%
Ratio P/B
580.17
P/FCF
1049.76
Marge brute
59.6%
ROIC
12.3%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
12.3%
WACC
8.5%
ROIC − WACC
+3.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critères d'analyse fondamentale
Réussi (10)
- ROIC 12.3%
- Gross Margin 59.6%
- Debt/Equity ratio
- Operating Margin 28.5%
- Positive Free Cash Flow
- Debt/EBITDA
- ROE 42.9%
- Analyst Consensus 76% Buy
- PEG Ratio 0.47
- Net Margin Trend 22.4% vs 10.1%
Échoué (11)
- Price CAGR -3.27%
- P/FCF 1049.76
- P/B Ratio 580.17
- CapEx intensity
- Current Ratio
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 0.3%
- Earnings Surprise avg 2.4%
- Earnings Quality (OCF/NI) 0.66
- Piotroski F-Score 1/9
Indisponible (6)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Share Dilution (missing shares data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Modérée : certain écart entre profits et trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Kristoffer Loe Licht | CEO & Executive Director | 49 |
| Ms. Shannon Sue Eisenhardt | CFO & Executive Director | 51 |
| Mr. Nicholas James Ashworth C.F.A. | Senior Vice President of Investor Relations | - |
| Ms. Catheryn O'Rourke | Senior VP, General Counsel & Company Secretary | 52 |
| Ms. Sheila Redzepi | Chief Communications & Corporate Affairs Officer | 46 |
| Mr. Ranjay Radhakrishnan | Chief Human Resources Officer | 54 |
| Mr. Jerome Lemaire | President North America | 51 |
| Ms. Angela Naef Ph.D. | Chief Research & Development Officer | 49 |
| Ms. Susan Sholtis | President of Nutrition | 58 |
| Dr. Alessio Fasano M.D. | Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business | - |
Risque d'audit
4
Risque du conseil
2
Risque de rémunération
3
Risque droits des actionnaires
1
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for RBGPF, sourced from Markets Gazette.